We are live on !
Find out more
NVP Associates Portfolio holdings
AUM
$328M
Turnover
50%
1-Year Est. Return
166.51%
This Fund
S&P 500
This Quarter Est. Return
+56.12%
1 Year Est. Return
+166.51%
3 Year Est. Return
+953.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$152M
(+86%)
Cap. Flow
+$46.2M
Cap. Flow % of AUM
Cap. Flow %
14.08%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
3
Increased
–
Reduced
–
Closed
1
Avg Time Held
1.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalyn Pharma
AVLN
|
+$65.5M |
| 2 |
Snowflake
SNOW
|
+$21.1M |
| 3 |
Ondas Inc
ONDS
|
+$154K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BillionToOne Inc
BLLN
|
+$40.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.83% |
| 2 | Technology | 8.94% |
| 3 | Consumer Staples | 1.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
MBX Biosciences
MBX
$2.65B
| $118M | 35.93% |
2,136,335
| – | – |
2024 Q3
7 quarters
|
|
|
2
Avalyn Pharma
AVLN
$1.19B
| $74.7M | 22.75% |
+2,268,404
| New | +$65.5M |
2026 Q2
0 quarters
|
|
3
Omada Health Inc
OMDA
$1.14B
| $55.6M | 16.93% |
2,531,000
| – | – |
2025 Q2
4 quarters
|
|
4
Zenas BioPharma
ZBIO
$1.85B
| $46.7M | 14.22% |
1,838,482
| – | – |
2024 Q3
7 quarters
|
|
|
5
Snowflake
SNOW
$104B
| $29.2M | 8.9% |
+114,786
| New | +$21.1M |
2026 Q2
0 quarters
|
|
6
Grove Collaborative
GROV
$47.4M
| $4.03M | 1.23% |
3,225,097
| – | – |
2022 Q4
14 quarters
|
|
|
7
Ondas Inc
ONDS
$3.37B
| $129K | 0.04% |
+15,602
| New | +$154K |
2026 Q2
0 quarters
|
|
|
8
BillionToOne Inc
BLLN
$5.21B
| – | – |
-513,330
| Closed | -$40.5M | – |
|
Similar funds
TM
NVP Associates's Q2 2026 Portfolio in Review
As of Q2 2026, NVP Associates held 8 positions worth $328M, up 86% from $176M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
NVP Associates deployed $46.2M of net new capital in Q2 2026, opening 3 new positions. Its largest new stake was Avalyn Pharma: 2,268,404 shares worth $74.7M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the most notable exit was BillionToOne Inc, an estimated $40.5M sold.
- NVP Associates's largest Q2 2026 buy was Avalyn Pharma: 2,268,404 shares worth $74.7M.
- NVP Associates fully exited BillionToOne Inc in Q2 2026, selling an estimated $40.5M.
- NVP Associates's ten largest holdings make up 100% of its $328M portfolio in Q2 2026.
- NVP Associates opened 3 new positions and closed 1 in Q2 2026.
- NVP Associates's portfolio value rose 86% quarter-over-quarter to $328M.
Based on NVP Associates's 13F filing for Q2 2026, filed 7 Aug 2026.